Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Liabilities (2016 - 2026)

Corvus Pharmaceuticals' Total Liabilities history spans 12 years, with the latest figure at $12.5 million for Q1 2026.

  • Quarterly Total Liabilities rose 23.76% to $12.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Mar 2026, up 23.76% year-over-year, with the annual reading at $9.9 million for FY2025, 72.72% down from the prior year.
  • Total Liabilities came in at $12.5 million for Q1 2026, up from $9.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $46.4 million in Q3 2024 to a low of $6.7 million in Q1 2024.
  • The 5-year median for Total Liabilities is $10.1 million (2025), against an average of $14.0 million.
  • Year-over-year, Total Liabilities surged 506.38% in 2024 and then tumbled 81.24% in 2025.
  • Corvus Pharmaceuticals' Total Liabilities stood at $12.1 million in 2022, then plummeted by 43.35% to $6.9 million in 2023, then surged by 429.03% to $36.3 million in 2024, then plummeted by 72.72% to $9.9 million in 2025, then increased by 26.25% to $12.5 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Total Liabilities are $12.5 million (Q1 2026), $9.9 million (Q4 2025), and $8.7 million (Q3 2025).